Delivering your deuterium
innovation is our duty.
One solution at a time.
Welcome to
deutraMed™
deutraMed™ is a breakthrough deuterium science and innovation company.
We meet the growing demand for value-added deuterium-containing ingredients used mainly in the Life Sciences and High Technology sectors. We also provide research and services for next-generation deuterium products in partnership with our clients and conduct IP-driven R&D for bio-pharma and bio-materials applications.
deutraMed’s advanced R&D, supported by a world-class Scientific Advisory Board, helps our clients achieve their business goals and contributes to a healthier, more connected world.
Our Services
Deuterium Products
Deuterium Precursors and Intermediates are used for a variety of applications in the high technology and life science sectors.
Deuterium Expertise & Supply
We are your partner for deuterium expertise and access to the strongest deuterium supply chain possible.
Deuterium CRO & CMO Services
At deutraMed™, we are committed to empowering our customers to innovate with deuterium.
mRNA Therapeutics
Our Cost-Saving Solution Improves mRNA Stability During Synthesis and Storage
Deuterium Innovations
We are developing new products based on client demands. We transform your deuterium challenges into solutions.
Scientific Advisory Board
The members of deutraMed’s Scientific Advisory Board draw on a wide array of deuterium expertise and professional experience to advise the company on its science and innovation-focused activities. They meet periodically to peer review the company’s scientific work, provide expert input on research proposals, and share ideas for the exploration of new breakthrough innovations.
Joseph P. Porwell, BS, PhD
Former President, Aldrich Chemical Company
Chair of the Scientific Board
Dr. Porwoll has had a close association with deutraMed that includes service on the Board of Directors and advisory services to expand the company’s deuterium capabilities in both business and science. As the former President of Aldrich and VP of Supply Chain of Sigma Aldrich, Dr. Porwoll’s knowledge of customer requirements, products and technical isotopic expertise is world-class. He has developed, manufactured and managed various stable isotope production systems, including those with deuterium.
Alistair I. Miller, BSc, PhD, DIC, FCIC
Former Head of Hydrogen Isotopes Group, AECL
Scientific Advisory Board Member
Dr. Miller has helped guide the scientific direction of deutraMed since its inception. During a more than 40-year career, he has gained extensive experience in hydrogen isotope separation, deuterium oxide technology and nuclear energy. He is the retired former head of the Hydrogen Isotopes Group of Atomic Energy of Canada Limited and is a listed inventor on numerous patents who is recognized as an expert in the field of deuterium oxide technology. Dr. Miller has a B.Sc. in Applied Chemistry from the University of Glasgow and a Ph.D. in Chemical Engineering from the University of London (Imperial College). He is a Past President of the Canadian Society for Chemical Engineering.
Graham Murphy, BSc, PhD
Associate Professor, University of Waterloo
Scientific Advisory Board Member
Dr. Murphy has been engaged with deutraMed since 2017, guiding the development of deuterated organic synthesis processes. His research is focused on organic chemistry, specifically the development of hypervalent iodine reagents. These reagents are key to his work developing new methods for carbene formation, C-C bond formation and α-carbonyl functionalization – chemistry that in turn is used to develop designer electrolytes for battery technologies and to target natural medicinal products.
Denis Gris, BHSc, PhD
Professor of Immunology, Université de Sherbrooke
Scientific Advisory Board Member
Professor Gris began his association with deutraMed in 2020, in the field Bio-Pharmaceuticals.. Professor Gris earned a Masters degree and Ph.D. in Neuroscience at Dr. Lynn Weaver’s laboratory at the University of Western Ontario, where he discovered that the influx of neutrophils is detrimental for recovering after spinal cord injury.
Samantha E. L. Stuart, BASc, MASc, EIT
Data Scientist, Machine Learning Researcher, University of Toronto
Scientific Advisory Board Member
Ms. Stuart has contributed to scientific innovations and intellectual property management at deutraMed since its inception. A University of Toronto National Scholar, Ms. Stuart completed her MASc in Biomedical Engineering at the university, with a focus on machine learning in nanomedicine at the Frank Gu Lab. There, she co-founded an open science platform based on her research developing a framework for the machine-learning driven design of nanoparticle drug delivery systems targeting mucosal membranes. Samantha is an author of several peer reviewed papers and has developed multiple open-source code repositories, and today builds cutting edge cloud technology platforms in the business world as a Professional Services Consultant.
Memberships
